Brief: Olix Pharmaceuticals Announces Ind Submission To U.S. FDA To Evaluate Safety And Tolerability Of Olx10212 In Phase 1 Clinical Trial
01/07/2022 13:01
July 1 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS ANNOUNCES IND SUBMISSION TO U.S. FDA
TO
EVALUATE SAFETY AND TOLERABILITY OF OLX10212 IN PHASE 1 CLINICAL
TRIAL
Source text for Eikon: ID:nBwbg1Lhba
Further company coverage: 226950.KQ
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals - Olx501a Shows 29.2% Visceral Fat Reduction Versus 10.0% With Comparator In Obese Non-Human Primates
Brief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug